Atara Biotherapeutics Inc
NASDAQ:ATRA
Intrinsic Value
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematol... [ Read More ]
The intrinsic value of one
ATRA
stock under the Base Case scenario is
7.2541
USD.
Compared to the current market price of 0.6998 USD,
Atara Biotherapeutics Inc
is
Undervalued by 90%.
Atara Biotherapeutics Inc's market capitalization is 74.5m USD.
ATRA stock price is 0.6998 USD.
ATRA stock price (0.6998 USD) is 90% less than its Intrinsic Value (7.2541 USD).
ATRA. Open DCF Valuation
ATRA stock price (0.6998 USD) is 90% less than its Relative Value (7.2541 USD). Open Relative Valuation
ATRA has upside potential of 512% compared to the average analyst price target.
Open Wall St Estimates
ATRA has negative Net Debt. This means that the company has more cash and short-term investments (52m USD) than debt (35m USD).
ATRA's Revenue has dropped by 87% over the past 12 months.
ATRA's ROE (Return on Equity) has significantly decreased in the last 3 years from -96% to -2 018%, and is approaching profitability.
ATRA's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -407% to -227%, and is approaching profitability.
ATRA's short-term liabilties (142m USD) exceed its short-term assets (102m USD).
ATRA has negative Gross Profit for the last twelve months.
ATRA's long-term liabilties (265m USD) exceed its long-term assets (166m USD).
ATRA has negative Operating Income for the last twelve months.
ATRA has negative Net Income for the last twelve months.
ATRA's ROE (Return on Equity) for the past 12 months is negative and is equal to -2 018%.
ATRA's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -227%.
ATRA's Revenue is forecast to grow at a rate of 101% per year over the next 3 years.
ATRA has negative Free Cash Flow for the last twelve months.
ATRA has negative three-year average ROE (Return on Equity): -284%. The company is not efficient at transforming stockholders' equity into net income.
ATRA has negative three-year average ROIC (Return on Invested Capital): -363%. The company is not efficient at using invested capital to generate operating income.
ATRA's D/E (Debt to Equity) is very low and is equal to -0.35.
ATRA's Altman Z-Score is very low and is equal to -22.52.
ATRA doesn't generate enough operating income (-269m USD) to safely cover interest payments on its debt (447k USD).
Valuation Backtest
Atara Biotherapeutics Inc
Run backtest to discover the historical profit from buying and selling
ATRA
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Atara Biotherapeutics Inc
Balance Sheet Decomposition
Atara Biotherapeutics Inc
| Current Assets | 101.9m |
| Cash & Short-Term Investments | 51.7m |
| Receivables | 34.1m |
| Other Current Assets | 16m |
| Non-Current Assets | 63.6m |
| PP&E | 58.8m |
| Other Non-Current Assets | 4.8m |
| Current Liabilities | 142.2m |
| Accounts Payable | 3.7m |
| Accrued Liabilities | 59.8m |
| Other Current Liabilities | 78.7m |
| Non-Current Liabilities | 122.5m |
| Long-Term Debt | 34.7m |
| Other Non-Current Liabilities | 87.9m |
Earnings Waterfall
Atara Biotherapeutics Inc
|
Revenue
|
8.6m
USD
|
|
Cost of Revenue
|
-8.9m
USD
|
|
Gross Profit
|
-313k
USD
|
|
Operating Expenses
|
-269m
USD
|
|
Operating Income
|
-269.3m
USD
|
|
Other Expenses
|
-6.9m
USD
|
|
Net Income
|
-276.1m
USD
|
Free Cash Flow Analysis
Atara Biotherapeutics Inc
ATRA Profitability Score
Profitability Due Diligence
Atara Biotherapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Atara Biotherapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
ATRA Solvency Score
Solvency Due Diligence
Atara Biotherapeutics Inc's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Score
Atara Biotherapeutics Inc's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ATRA Price Targets Summary
Atara Biotherapeutics Inc
According to Wall Street analysts, the average 1-year price target for
ATRA
is 4.284 USD
with a low forecast of 0.505 USD and a high forecast of 13.65 USD.
Ownership
ATRA Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ATRA Price
Atara Biotherapeutics Inc
| Average Annual Return | -31.9% |
| Standard Deviation of Annual Returns | 43.91% |
| Max Drawdown | -99% |
| Market Capitalization | 74.5m USD |
| Shares Outstanding | 101 922 000 |
| Percentage of Shares Shorted | 9.61% |
Company Profile
Atara Biotherapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. The company is headquartered in South San Francisco, California and currently employs 578 full-time employees. The company went IPO on 2014-10-16. The firm is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune disease. Its platform leverages the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other serious diseases through engineered chimeric antigen receptors (CARs) or T-cell receptors (TCRs). The Company’s pipeline products include Tab-cel, ATA188, ATA2271, ATA3271 and ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA188 is a T-cell immunotherapy for the treatment of multiple sclerosis.
Contact
IPO
Employees
Officers
The intrinsic value of one
ATRA
stock under the Base Case scenario is
7.2541
USD.
Compared to the current market price of 0.6998 USD,
Atara Biotherapeutics Inc
is
Undervalued by 90%.
You don't have any saved screeners yet
